ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 861

CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice

Sho Sendo1, Jun Saegusa1, Hirotaka Yamada2, Yoshihide Ichise2, Ikuko Naka3, Yo Ueda2, Takaichi Okano2, Soshi Takahashi4, Kengo Akashi5, Akira Onishi6 and Akio Morinobu4, 1Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 2Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 3Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 4Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 5Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, 6Department for Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: animal models and tolerance, Dendritic cells, interstitial lung disease, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Animal Models

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice

 

Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated ILD (RA-ILD) in human. We identified a new cell population, CD11b+Gr1dim cells, in the lung of zymosan A (ZyA)-treated SKG mice. The purpose of this study is to elucidate the origin and the function of CD11b+Gr1dim cells, in the pathogenesis of ILD in SKG mice.
Methods: We assessed the severity of ZyA-induced ILD in SKG mice histologically, and examined lung-infiltrating cells by flow cytometry. Total lung cells and isolated monocytic myeloid-derived suppressor cells (M-MDSCs) were cultured in vitro with GM-CSF (and IL-4). The proliferation of CSFE-labeled naïve T cells co-cultured with isolated CD11b+Gr1dim cells and MDSCs was evaluated by flow cytometry. In vitro-generated CD11b+Gr1dim cells were transferred to ZyA-treated SKG mice.
Results: Histological analysis revealed that ZyA-treated mice developed various severity of ILD; HS1: 25%, HS2: 50% and HS3: 25%. MDSCs, Th17 cells, and group 1 and 3 innate lymphoid cells (ILC1s and ILC3s) were increased in the lungs; the proportion of these cells varied with ILD severity. In this process, we found that a unique cell population, CD11b+Gr1dim cells, was expanded in the lungs with diffusely affected area greater than 60%. About half of the CD11b+Gr1dim cells expressed CD11c, and the cells were morphologically DC-like. The CD11b+Gr1dim cells were induced from M-MDSCs with GM-CSF in vitro and were considered tolerogenic because they suppressed T-cell proliferation and expressed high levels of PD-L1. The regulatory function of CD11b+Gr1dimcells was partially canceled by addition of Anti-TGF-beta neutralizing antibody when generating them. The CD11b+Gr1dim cells have never described previously and termed CD11b+Gr1dim tolerogenic dendritic cell-like cells (CD11b+Gr1dim tolDC-LCs). Furthermore, adoptive transfer of CD11b+Gr1dim tolDC-LCs significantly suppressed the progression of ILD in SKG mice.

Conclusion: CD11b+Gr1dim tolDC-LCs were differentiated from M-MDSCs, and could suppress the progression of ILD in SKG mice.


Disclosure: S. Sendo, None; J. Saegusa, None; H. Yamada, None; Y. Ichise, None; I. Naka, None; Y. Ueda, None; T. Okano, None; S. Takahashi, None; K. Akashi, None; A. Onishi, None; A. Morinobu, None.

To cite this abstract in AMA style:

Sendo S, Saegusa J, Yamada H, Ichise Y, Naka I, Ueda Y, Okano T, Takahashi S, Akashi K, Onishi A, Morinobu A. CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/cd11bgr1dim-tolerogenic-dendritic-cell-like-cells-suppress-the-progression-of-interstitial-lung-disease-in-skg-mice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd11bgr1dim-tolerogenic-dendritic-cell-like-cells-suppress-the-progression-of-interstitial-lung-disease-in-skg-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology